Cutaneous Reactions in Patients with Chronic Hepatitis C Treated with Peginterferon and Ribavirin

    January 2014 in “ Dermatology
    Ivana Patrk, Miro Morović, Anamarija Markulin, Jogen Patrk
    Image of study
    TLDR Some patients treated with peginterferon and ribavirin for chronic hepatitis C had mild to moderate skin reactions, but treatment did not need to be stopped.
    In a 6-year prospective study of 271 patients with chronic hepatitis C treated with peginterferon and ribavirin, 36 (13.3%) experienced cutaneous reactions, which were generally mild to moderate. These included localized reactions in 7 (2.6%) patients, generalized reactions such as pruritus, skin xerosis, and eczematous changes in 28 (10.3%) patients, and alopecia in 11 (4.1%) patients. The study found that these reactions were more common in older patients and those with longer treatment durations, but there was no significant correlation with gender, genotype, fibrosis stage, or sustained viral response, although males were more prone to alopecia. The prevalence of cutaneous reactions was low enough that it did not require stopping the treatment, and the paper highlights the importance of monitoring and managing these reactions, especially considering the genetic susceptibility to conditions like alopecia areata. No financial disclosures or conflicts of interest were reported in the document.
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results

    Related Community Posts Join

    6 / 1000+ results
      If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied

      community If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied

      in Research  830 upvotes 5 months ago
      Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

      community Kintor Phase 2 Results released KX-826 (pyrilutamide)

      in Research/Science  450 upvotes 2 years ago
      Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
      [object Object]

      community Alopecia Areata Question

      in Treatment  2 upvotes 3 years ago
      A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.

    Similar Research

    5 / 1000+ results